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the value we give corresponds to the Sidak-adjusted
threshold ( ). As such, this example nicely1/k1 [1 a]
illustrates that permutation testing, for two indepen-
dent tests, yields familiar and contextually appropriate
results.
It should also be noted that multiple-testing methods
that rely on raw Bonferroni-type inequalities fail to in-
corporate correlation structures between tests. There-
fore, although such methods (e.g., Simes 1986; Hoch-
berg 1988; Rom 1990) provide control of FWE, they
nevertheless are expected to be less powerful than meth-
ods that account for such dependencies. Indeed, these
methods may be made more precise through resampling-
based approaches (Westfall and Young 1993). In par-
ticular, the data from which the tests in table 7 (Bugawan
et al. 2003) were derived are strongly correlated, and,
therefore, tests that assume independence are not ex-
pected to be the most powerful. Moreover, Kraft fails
to take into account the nonindependence of genotype
distributions between chromosome 5 and chromosome
16 SNPs presented in table 6 (Bugawan et al. 2003).
Applying the Simes correction suggested by the author
for 10 comparisons (two sets: patients and controls, and
ﬁve SNPs), the independence between IL4-524 and IL4R
patient genotypes would be rejected with , sup-P ! .01
porting our conclusion of an interaction between chro-
mosome 5 and chromosome 16 in T1D susceptibility.
In conclusion, what is needed, from a methodological
perspective, are statistical procedures that adequately
protect against false claims of signiﬁcance while simul-
taneously addressing the correlated nature of multiple
testing. The various methods discussed by Kraft address
the former but do not address the latter. Having said
this, whatever the statistical approach, the strongest test
of the signiﬁcance of any reported genetic interaction
lies neither in initial-discovery P values nor in biologic
plausibility—which we believe is high in this case—but
in the ability to reproduce observations in independent
cohorts.
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Revisiting the Clinical Validity of Multiplex Genetic
Testing in Complex Diseases
To the Editor:
The usefulness of genetic testing to identify high-risk
patients for common multifactorial diseases is subject to
debate. Optimism about the public health opportunities
is counterbalanced with skepticism, since genetic factors
appear to play a role in only a minority of patients with
complex diseases, the number of genes involved is large,
and their penetrance is incomplete (Holtzman and Mar-
teau 2000; Vineis et al. 2001).
In last March’s issue of the Journal, Yang and col-
leagues addressed the question of whether prediction of
disease is improved by multiplex genetic testing (Yang
et al. 2003). At ﬁrst sight, their results seem promising.
In a simulation study, they considered ﬁve genetic tests
(g1–g5), which each could have a positive ( ) org p 1i
negative result ( ). Yang et al. used the likelihoodg p 0i
ratio to indicate the magnitude of change in disease
probability before and after genetic testing. Positive test
586 Letters to the Editor
Figure 1 Probability of disease before and after testing for multiple genes and environmental exposure. The two-gene test has 4 (22)
possible test results, the three-gene test has 8 (23) results, and so on. The posterior probability of disease for each combination of test results
is obtained from the regression equations in table 1 of Yang et al. (2003).The prevalence of each combination is calculated by multiplying the
probabilities of positive (p) and negative ( ) test results of each single test. For example, for the two-gene test we calculate that 60%1 p
([10.25] # [10.20] # 100) of the individuals will have negative results on both tests and 15% ([10.25] # 0.20 # 100) will have a
negative result on test 1 and a positive result on test 2. To facilitate presentation of all results, a cumulative prevalence (X-axis) was calculated,
which was obtained by summing the prevalences after ranking the outcomes on their posterior probability.
results have a likelihood ratio 11, which means that the
posterior disease probability is higher than the prior
probability. Negative test results have a likelihood ratio
!1. The combined likelihood ratio of several indepen-
dent test results can be obtained by multiplying their
individual likelihood ratios. Using these principles, Yang
et al. showed that combining information on ﬁve genetic
factors and one environmental exposure in one multi-
plex test may increase a 5% baseline risk to 88.9%,
which was considerably higher than the posterior prob-
abilities obtained by testing for the single genes (7.8%–
16.4%). In addition, they demonstrated using empirical
data from a study on deep venous thrombosis that the
posterior probability of venous thrombosis was sub-
stantially higher when three genes, factor V Leiden,
G20210A prothrombine, and protein C deﬁciency, were
considered simultaneously (61.6%), rather than each
gene alone (1.2%–3.1%). These estimates are correct,
but they do not demonstrate the clinical validity of mul-
tiplex genetic testing, as the authors concluded. There
are four reasons for this.
First, Yang et al. based their conclusion on only one
outcome of the composite test—that is, the combination
of positive results on all individual tests. Although Yang
et al. acknowledged in their discussion that this concerns
only a small proportion of the population, they did not
quantify the size of the proportion. From multiplication
of the prevalences of the test results, we calculate that
the 18-fold increase in probability of disease in the sim-
ulated data was found in 0.0006% (6 per million) of all
subjects and the 100-fold increase in the risk of venous
thrombosis in only 0.0004% (4 per million). This low
prevalence of high-risk combinations of genes may limit
the clinical usefulness of genetic testing.
The second point is related to this issue. Yang et al.
presented disease probabilities for subjects who had pos-
itive results on all single tests, but they did not report
the probabilities for subjects who had combinations of
both positive and negative results. The posterior prob-
abilities and prevalences of all test result combinations
are presented in ﬁgure 1. This ﬁgure demonstrates that
the probabilities that Yang et al. had reported are the
highest points in each of the graphs. Although these
probabilities increase when genes are added, the prob-
abilities of all other test result combinations do not rise
accordingly. This is explained by the fact that positive
results on each single test increase the combined likeli-
hood ratio. This implies that the posterior probabilities
reported by Yang et al. increase by deﬁnition when tests
are added. In all other combinations with one or more
negative test results, the likelihood ratios of negative
results on the single tests will decrease the overall like-
lihood ratio. For the majority of subjects, the beneﬁts
of multiplex genetic testing in terms of the difference
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Figure 2 ROC curves for the multiplex genetic tests of Yang et
al. (2003).
between the prior and posterior probability are less
profound.
A third point is that each genetic test that was added
by Yang et al. was a stronger predictor of disease than
those already considered in the multiplex test. The rel-
ative risks of the positive test results increased from 1.5
to 3.5, with likelihood ratios ranging from 1.6 to 3.7.
This implies that the increase in the likelihood ratio of
the composite test results may not only be due to the
addition of tests but probably also to their higher pre-
dictive values. If the likelihood ratio of each single test
had been 1.7, similar to the ﬁrst test, then the combined
likelihood ratio for subjects who had positive results on
all ﬁve tests would have been 14.2, much lower than
the 77.6 reported by Yang et al. This demonstrates that
the substantial increase in the likelihood ratio was
largely explained by the increasing predictive value of
the single genes. In general, the added value of expanding
a multiplex test will depend on the predictive value of
each individual genetic test.
The fourth point concerns the most important con-
clusion of the authors that multiplex genetic testing has
the potential to improve the clinical validity of predictive
testing for common multifactorial diseases. This conclu-
sion was based on the substantial increase in the prob-
ability of disease of individuals who had positive results
on all single tests. However, the clinical validity of a test
does not depend on the posterior probability for a few
subjects, but on its ability to discriminate between the
probability of disease in subjects who will develop the
disease and those who will not. The discriminative abil-
ity of a test is commonly evaluated by its sensitivity and
speciﬁcity. The sensitivity of a test is the percentage of
positive test results among subjects who will develop the
disease, and the speciﬁcity is the percentage of negative
test results among subjects who will not develop the
disease. On a perfect, or “gold-standard,” test, all sub-
jects who will develop the disease have a positive test
result (sensitivity p 1), and all subjects who will not
develop the disease have a negative result (speciﬁcity p
1). For composite tests, positive and negative results are
deﬁned by a cutoff value of the disease probability. The
sensitivity and speciﬁcity of a composite test may differ,
depending on the cutoff probability that is chosen.
Therefore, the sensitivity and speciﬁcity are calculated
for each possible cutoff value of the probability and
plotted in a so-called receiver-operating–characteristic
(ROC) curve (Hanley andMcNeil 1982). The area under
the ROC curve (AUC) indicates the discriminative ability
of a composite test. The discriminative ability is perfect
if the AUC is 1, whereas an AUC of 0.50 indicates a
total lack of discrimination (Hanley and McNeil 1982).
If one is interested in whether genetic tests can improve
the accuracy of prediction above and beyond certain
minimum levels of sensitivity or speciﬁcity, one may also
consider analyses of a partial AUC (e.g., Thompson and
Zucchini 1989). The ROC curves for the composite tests
considered by Yang et al. are presented in ﬁgure 2. The
total AUC increases from 0.59 for the two-gene test to
0.70 for the ﬁve-gene test, which means that adding
genes improves the discriminative ability of themultiplex
genetic test. Also here, one may question whether this
increase was due to the addition of genes or to their
increasing predictive values. To examine this, we con-
sidered the relative risks in equal steps from 1.5 to 1.7,
rather than from 1.5 to 3.5, which is more realistic for
genetic factors in common diseases. With these lower
relative risks, the AUC of the two-gene test was 0.57
and that of the ﬁve-gene test was 0.61. This difference
between the AUCs was smaller than that obtained from
the data from Yang et al., which implies that also the
increase in the discriminative ability of their multiplex
tests is largely explained by the increasing predictive
value of the added tests.
What can we learn from the ROC curve about the
clinical validity of genetic testing? The aim of genetic
screening is often to select high-risk subjects for preven-
tive treatment or intensiﬁed surveillance programs. For
this purpose, the sensitivity of the test should be high
so that most (future) patients are identiﬁed by a positive
test result. A high speciﬁcity of the test is desired to
increase the efﬁciency of screening, because then the
number of subjects who are unnecessarily selected for
preventive interventions is minimized. From ﬁgure 2 it
follows that a sensitivity of 0.80, which means that still
20% of the patients are missed by the screening pro-
gram, is accompanied by a speciﬁcity of 0.45. The latter
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means that 55% of all subjects who will not develop
the disease will be classiﬁed falsely. In a population in
which 95% of the individuals will not develop the dis-
ease, as in the study of Yang et al., this means that 52%
will undergo unnecessary preventive treatment. When a
sensitivity of 0.90 is chosen, the percentage of all subjects
who are unnecessarily selected is 73%. In comparison,
the sensitivity and speciﬁcity of mammography in a large
population–based breast cancer screening program were
0.75 and 0.92, respectively (Carney et al. 2003). Thus,
the multiplex genetic tests of Yang et al. are by no means
efﬁcient screening strategies.
In conclusion, the clinical usefulness of genetic testing
should be evaluated by ROC analysis. Using this ap-
proach for the data of Yang et al., we found that the
discriminative ability of the multiplex genetic test in-
creased by the addition of more genes but that its per-
formance for use as a screening instrument was rather
inefﬁcient. It remains to be investigated whether these
results are representative of the prediction of common
disease by multiplex genetic tests that include genetic
factors with low mutation prevalence and low relative
risks. In that case, alternative statistical strategies are
needed to increase the potential clinical application of
selective genetic testing.
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Revisiting the Clinical Validity of Multiplex Genetic
Testing in Complex Diseases: Reply to Janssens et al.
To the Editor:
We appreciate the comments by Janssens and her as-
sociates (2004 [in this issue]) regarding our study on the
use of likelihood ratios to improve the prediction of
complex diseases by testing for multiple-susceptibility
genes (Yang et al. 2003). As Janssens et al. correctly
point out, our study considers only the predicted prob-
ability of disease for subjects who have all positive test-
ing results, and this is likely to be an infrequent occur-
rence. We think that the suggestion made by Janssens et
al. to use receiver-operating–characteristic (ROC) curves
to assess multiple genetic testing is very useful. The ROC
curves provide a valuable way of evaluating the accuracy
and discriminatory ability of diagnostic tests (Hanley
1989). Janssens et al. use the ROC curves to assess the
classiﬁcation of patients into a disease group, but mul-
tiplex genetic testing is likely also to be of value in iden-
tifying people who are at lower-than-average risk for
developing a particular disease. This might allow them
to put off receiving a more expensive intervention for
some time—for example, to defer mammography for
breast cancer detection for 10 years (Fletcher 1997) or
to avoid screening for prostate cancer until 60 years
of age (Harris and Lohr 2002).
The predictive value of combining tests obviously does
depend on the relative risk associated with each com-
ponent test, with a bigger effect resulting from tests that
make larger independent contributions. Janssens et al.
suggest that an odds ratio of 1.5–1.7 for each test is
more likely than an odds ratio of 3.5. This might be
true, but we do not yet know what the relative frequency
of genes of larger or smaller effect will turn out to be
for any common multifactorial disease. We used ﬁve ge-
netic tests and an environmental factor as a simpliﬁed
illustration in our analysis, but, in the near future, 50
